



Fig. S2

Figure S2:

Drug resistance capabilities of CD133<sup>+</sup> cells. (A) Cell viabilities of PLC8024 (*PLC*), HepG2, and Hep3B-2 cells treated with paclitaxel (*taxol*) or cisplatin at the indicated concentrations. The cell viability was examined by the MTT assay after treatment for 24hrs. (B) Cell viability of isolated CD133<sup>+</sup> and CD133<sup>-</sup> PLC8024 treated with 0.1  $\mu$ M taxol or 100 $\mu$ g/ml cisplatin. The cell viability was examined by the MTT assay after treatment for 24hrs. (C) Hep3B cells infected with virus of nonsense or RNAi 1# against CD133 and treated with 0.5 $\mu$ M taxol or 5 $\mu$ g/ml cisplatin. The cell viability was examined by the MTT assay after treatment for 24hrs. All results were mean  $\pm$ SD from at least three independent experiments. \**P*<0.05.